MGA Mutation as a Novel Biomarker for Immune Checkpoint Therapies in Non-Squamous Non-Small Cell Lung Cancer
Background: Immune checkpoint inhibitors have changed the treatment landscape for advanced non-small cell lung cancer. However, only a small proportion of patients experience clinical benefit from ICIs. Thus, the discovery of predictive biomarkers is urgently warranted. Evidence have shown that gene...
Saved in:
Main Authors: | Lei Sun (Author), Man Li (Author), Ling Deng (Author), Yuchun Niu (Author), Yichun Tang (Author), Yu Wang (Author), Linlang Guo (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2021-04-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Prognosis of Lung Adenocarcinoma Patients With NTRK3 Mutations to Immune Checkpoint Inhibitors
by: Yuchun Niu, et al.
Published: (2020) -
Co-mutations of TP53 and KRAS serve as potential biomarkers for immune checkpoint blockade in squamous-cell non-small cell lung cancer: a case report
by: Cheng Fang, et al.
Published: (2019) -
Exploring histological predictive biomarkers for immune checkpoint inhibitor therapy response in non-small cell lung cancer
by: Uiju Cho, et al.
Published: (2024) -
The importance of EGFR mutation testing in squamous cell carcinoma or non-small cell carcinoma favor squamous cell carcinoma diagnosed from small lung biopsies
by: Hsiang-Ling Ho, et al.
Published: (2019) -
The role of ERBB4 mutations in the prognosis of advanced non-small cell lung cancer treated with immune checkpoint inhibitors
by: Xilin Hu, et al.
Published: (2021)